New Director Brings Strong Biotechnology Leadership
BOULDER, Colo., Apr 29, 2004 /PRNewswire-FirstCall via COMTEX/ -- Array BioPharma Inc.
(Nasdaq: ARRY) today announced the appointment of Douglas E. Williams, Ph.D.,
to its Board of Directors. His appointment is effective April 29.
Dr. Williams brings over 15 years of senior level biotech management
experience to Array's Board. He currently serves as Seattle Genetics' Chief
Scientific Officer and Executive Vice President of Research and Development,
and is a member of their Board of Directors. Previously, Dr. Williams served
at Immunex Corporation as Executive Vice President, Chief Technology Officer
and a member of Immunex's Board of Directors.
"Dr. Williams' extensive experience and outstanding reputation in the
biotech industry is a valuable asset for Array," said Kyle Lefkoff, Chairman,
Array BioPharma Board of Directors. "He will contribute valuable knowledge
and leadership as we aggressively expand and develop our product pipeline."
Prior to joining Seattle Genetics, Dr. Williams was Head of Health and
Strategic Development for Genesis Research & Development, a biotechnology
company located in New Zealand. From 2002 until 2003, he served as Senior
Vice President, Washington Site Leader and a member of the Executive Committee
for Amgen, Inc. Dr. Williams joined Amgen in July 2002 when it acquired
Immunex Corporation, where he worked for 14 years, most recently serving as
Executive Vice President, Chief Technology Officer and a member of Immunex's
Board of Directors. Prior to his work at Immunex, Dr. Williams served on the
faculty of the Indiana University School of Medicine and the Department of
Laboratory Medicine at the Roswell Park Memorial Institute. In addition to
Seattle Genetics, he serves on the board of Genesis Research & Development and
is Chairman of the Board of Amnis Corporation. Dr. Williams is a member of
the Scientific Advisory Board of Symphony Capital, New York. He also serves
as Chairman of the Board of Trustees of ArtsFund in Seattle. Dr. Williams
holds a B.S. magna cum laude in Biological Sciences from the University of
Massachusetts, Lowell and a Ph.D. in Physiology from the State University of
New York at Buffalo, Roswell Park Division.
"It's a great pleasure to be joining the board of Array BioPharma and to
have the opportunity to work with a talented team focused on bringing to
market innovative drugs for cancer and inflammation," said Dr. Williams.
About Array BioPharma:
Array BioPharma is creating the next generation of orally active drugs by
integrating the latest advances in chemistry, biology and informatics. Our
drug development pipeline is focused primarily in cancer and inflammatory
disease and includes many promising small molecule drugs that regulate
well-validated targets in therapeutically valuable disease pathways. Array
also collaborates with leading pharmaceutical and biotechnology companies to
invent and optimize drug candidates across a broad range of therapeutic areas.
For more information on Array, please go to www.arraybiopharma.com.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve
significant risks and uncertainties, including those discussed in our annual
report filed on Form 10-K for the fiscal year ended June 30, 2003, and in
other reports filed by Array with the Securities and Exchange Commission.
Because these statements reflect our current expectations concerning future
events, our actual results could differ materially from those anticipated in
these forward-looking statements as a result of many factors. These factors
include, but are not limited to, our ability to achieve and maintain
profitability, the extent to which the pharmaceutical and biotechnology
industries are willing to collaborate with and fund third parties on their
drug discovery activities, the ability of our collaborators and of Array to
meet drug discovery objectives tied to milestones and royalties, our ability
to continue to fund and successfully progress internal research efforts and to
create effective, commercially viable drugs, and our ability to attract and
retain experienced scientists and management. We are providing this
information as of April 29, 2004. We undertake no duty to update any
forward-looking statements to reflect the occurrence of events or
circumstances after the date of such statements or of anticipated or
unanticipated events that alter any assumptions underlying such statements.
SOURCE Array BioPharma Inc.
Tricia Haugeto of Array BioPharma Inc., +1-303-386-1193,